News


Special Message from the Executive Board


The Immuno Valley Foundation will come to an end by 31 December 2018. In its 10 years of existence, Immuno Valley has been at the base of a unique public-private infrastructure in the field of inflammatory and infectious diseases in the Netherlands. Together with partners, a number of powerful partnerships have been established and Immuno Valley has played an important role in the setting up the Netherlands Antibiotic Development Platform, NADP. Important consortium management activities have also been carried out for Bac Vactory, 2RealGuts, and other projects.  We thank you for your interest over the past 10 years.

Dear Immuno Valley Partner and Network Member,

As many of you have noticed in the past period, important developments have taken place at the Immuno Valley Foundation. 

This year a new design of the partner compensation structure came into effect. Among other things, to increase the flexibility of the partners with regard to the Immuno Valley service activities. Together with partners, a number of powerful partnerships have been established and Immuno Valley has played an important role in the setting up the Netherlands Antibiotic Development Platform, NADP. Important consortium management activities have also been carried out for BacVactory, 2RealGuts, and other projects.

Strengthening the financial base of Immuno Valley was another important objective in 2018. However, these efforts have unfortunately not led to the extra boost that Immuno Valley needed to achieve a stable financial base. Event recent orientations into new forms of collaboration in order to guarantee continuity have not offered any new opportunities.

The negative result, despite the hard work, in combination with the departure of managing director, Liana Steeghs, and project manager, Mijke Vogels, has made the Executive Board decide to end the activities of the Immuno Valley Foundation by 31 December 2018. Agreements have been made with the coordinators of the current projects on the transfer of tasks. This consultation has also taken place for projects in the start-up phase.

In its 10 years of existence, Immuno Valley has been at the base of a unique public-private infrastructure in the field of inflammatory and infectious diseases in the Netherlands. As the Executive Board, and also on behalf of the Immuno Valley team, we would like to thank you for your dedication over the past 10 years and the impact this has brought. We wish you a future where innovation and collaboration will lead to new insights and, more importantly, to new products or therapies for humans and animals.

Sincerely,

on behalf of the Immuno Valley Executive Board

Dr. René M.L. Aerts
Chair

 

  1. More news

  2. Highlights of celebrating 10 years Immuno Valley at the Annual Conference 2018

    We look back on a very successful Immuno Valley Conference 2018 which took place on September, 25th. National and international speakers presented the latest scientific breakthroughs, including innovative technologies and promising new products in the field of infectious and inflammatory diseases.


  3. All about the Immuno Valley Annual Conference 2018: Bringing together innovators in science, technology and business. Looking forward to meeting you too!

    The Immuno Valley Annual Conference is organised on 25 September 2018, at the Railway Museum, Utrecht, the Netherlands. At this Annual Conference we are also looking forward to celebrate our 10th Immuno Valley anniversary!


  4. Record amount of Measles cases in the European Region

    The World Health Organization (WHO) reported a dramatic increase in measles cases in 2018. In the first 6 months of 2018, more than 41,000 children and adults in the WHO European Region have been infected with measles, compared with 23,927 cases throughout 2017. This is an exponential increase, which could have been prevented if people go and get their vaccinations in time. As Zsuzsanna Jakab, WHO regional director for Europe, said in a statement: ‘Good health for all starts with immunization’.


  5. Micreos ‘Alternative to antibiotics’ winner of Ideas from Europe competition

    On April 26, 2018, Micreos was chosen as Europe’s most relevant innovation at the finals of the EU’s Ideas from Europe competition. Ideas from Europe is a European initiative that facilitates sustainable innovations aimed at global challenges.


  6. Proud to present our Annual Conference Speakers

    Top international speakers from academic institutions and businesses will let you explore developments and a forward look in diagnostics, prevention and treatment of inflammatory and infectious diseases in humans and animals .